Brief: Heidelberg Pharma: Partner Takeda Reached Development Milestone
08/08/2023 06:48
Aug 8 (Reuters) - Heidelberg Pharma AG HPHA.DE :
* PARTNER TAKEDA REACHED A DEVELOPMENT MILESTONE FOR
STARTING A
GLP (GOOD LABORATORY PRACTICE) TOXICOLOGY STUDY FOR AN ANTIBODY
TARGETED AMANITIN CONJUGATE
* RECEIVED A MILESTONE PAYMENT
* PAYMENT WAS ALREADY BUDGETED FOR IN HEIDELBERG PHARMA'S
FINANCIAL FORECAST FOR FINANCIAL YEAR 2023.
Source text for Eikon: ID:nEQkH46ra
Further company coverage: HPHA.DE
((frankfurt.newsroom@thomsonreuters.com;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments
Brief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty